<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04518982</url>
  </required_header>
  <id_info>
    <org_study_id>Sintilimab,Lenalidomide,CAEBV</org_study_id>
    <nct_id>NCT04518982</nct_id>
  </id_info>
  <brief_title>Sintilimab and Lenalidomide as a Treatment for CAEBV</brief_title>
  <official_title>Sintilimab and Lenalidomide as a Treatment for CAEBV：a Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhao Wang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Friendship Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multi-center, prospective, randomized, controlled clinical study to evaluate&#xD;
      the effectiveness of a combination regimen of Sintilimab and lenalidomide in patients with&#xD;
      chronic active EBV infection.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2020</start_date>
  <completion_date type="Anticipated">August 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>Twelve weeks after treatment</time_frame>
    <description>The rate of decline in ebV-DNA copy (defined as a 2log decrease in EBV-DNA copy) or negative rate in peripheral blood mononuclear cells and plasma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Spleen size</measure>
    <time_frame>Twelve weeks after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T and B lymphocyte subsets</measure>
    <time_frame>Twelve weeks after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathological tissue or bone marrow</measure>
    <time_frame>Twelve weeks after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>through study completion, an average of 1 years</time_frame>
    <description>Adverse events including thyroid function， liver function damage, myelosuppression, infection, bleeding and so on.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>survival</measure>
    <time_frame>1 year</time_frame>
    <description>From enrollment until death or the end of the experiment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">51</enrollment>
  <condition>CAEBV</condition>
  <arm_group>
    <arm_group_label>The experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>The control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sintilimab and lenalidomide</intervention_name>
    <description>Drug: Sintilimab 200mg ivgtt on day 1. Drug: lenalidomide 10mg orally once a day, day 1-14.</description>
    <arm_group_label>The experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sintilimab placebo and lenalidomide placebo</intervention_name>
    <description>Drug: Sintilimab placebo ivgtt on day 1. Drug: lenalidomide placebo orally once a day, day 1-14.</description>
    <arm_group_label>The control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with CAEBV confirmed by WHO criteria.&#xD;
&#xD;
          2. The Eastern United States Oncology Cooperative group (ECOG) Physical Status score is 0&#xD;
             or 1.&#xD;
&#xD;
          3. Before the study, aspartate aminotransferase (AST) and alanine aminotransferase (ALT)&#xD;
             ≤3× normal upper limit (ULN); Total bilirubin ≤2 times the normal upper limit; Serum&#xD;
             creatinine ≤1.5 times the normal value.&#xD;
&#xD;
          4. Absolute neutrophil count ≥1×109/L; Platelet ≥50×109/L; Hemoglobin ≥60 g/L.&#xD;
&#xD;
          5. International standardized ratio ≤2.0, prothrombin time ≤1.5×ULN.&#xD;
&#xD;
          6. A woman of childbearing age must be determined not to be pregnant by a pregnancy test&#xD;
             and is willing to take effective measures to prevent pregnancy during the trial period&#xD;
             and ≥12 months after the last administration of the drug; All male subjects used&#xD;
             contraceptive methods during the study period and ≥6 months after the last&#xD;
             administration;&#xD;
&#xD;
          7. Sign the informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. There is evidence that EBV is associated with hematologic disease or malignancy, such&#xD;
             as hemophagocytic syndrome, lymphoma-like granulomatosis, post-transplant&#xD;
             lymphoproliferative disease, non-Hodgkin's lymphoma, Burkitt lymphoma, nasopharyngeal&#xD;
             cancer, and gastric cancer.&#xD;
&#xD;
          2. Symptomatic EBV-associated diseases of the major organs, including the central nervous&#xD;
             system and lungs.&#xD;
&#xD;
          3. Abnormal thyroid function.&#xD;
&#xD;
          4. Patients with grade II or above heart disease (including grade II) were identified&#xD;
             according to the New York Heart Association (NYHA) score.&#xD;
&#xD;
          5. Have received any of the following treatments: PD-1 antibody, PD-L1 antibody or&#xD;
             lenalidomide; Received any research drug within 12 weeks prior to the first use of the&#xD;
             study drug; Another clinical study was also included.&#xD;
&#xD;
          6. Other primary malignancies occur within 5 years before the first administration of the&#xD;
             drug, except those that are locally curable after radical treatment (such as basal or&#xD;
             squamous cell skin cancer, superficial bladder cancer or carcinoma of the prostate,&#xD;
             cervix or breast in situ, etc.).&#xD;
&#xD;
          7. A history of organ transplantation (such as liver transplantation, kidney&#xD;
             transplantation, etc.).&#xD;
&#xD;
          8. Hematopoietic stem cell transplantation is expected during the study period.&#xD;
&#xD;
          9. Active hepatitis B (defined as hepatitis B surface antigen [HBsAg] positive during&#xD;
             screening, or hepatitis B virus DNA titer test in peripheral blood greater than 1×103&#xD;
             copies/ml), and active hepatitis C (defined as hepatitis C antibody [HCV-AB] and&#xD;
             HCV-RNA positive during screening). Serum HIV antigen or antibody positive. A history&#xD;
             of syphilis.&#xD;
&#xD;
         10. Had major surgery within 4 weeks prior to the first medication or was expected to&#xD;
             require major surgery during the study period.&#xD;
&#xD;
         11. Pregnant and lactating women;&#xD;
&#xD;
         12. A history of serious mental illness or drug abuse;&#xD;
&#xD;
         13. Uncontrollable infections (including lung infections, intestinal infections, etc.);&#xD;
             Internal organ active massive hemorrhage (including gastrointestinal hemorrhage,&#xD;
             alveolar hemorrhage, intracranial hemorrhage, etc.);&#xD;
&#xD;
         14. Allergic to the test drug ingredients or to a more severe allergic constitution;&#xD;
&#xD;
         15. Patients who cannot comply during the trial and/or follow-up phase.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>jingshi wang</last_name>
    <phone>86-010-63139862</phone>
    <email>wangjingshi987@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Friendship Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>jingshi wang</last_name>
      <phone>86-010-63139862</phone>
      <email>wangjingshi987@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 16, 2020</study_first_submitted>
  <study_first_submitted_qc>August 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 19, 2020</study_first_posted>
  <last_update_submitted>August 16, 2020</last_update_submitted>
  <last_update_submitted_qc>August 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Friendship Hospital</investigator_affiliation>
    <investigator_full_name>Zhao Wang</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenalidomide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

